1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Astellas Misses Again On Xospata Label Expansion Effort

 
• By Joseph Haas

A Phase III disappointment in a maintenance therapy setting for FLT3-mutated acute myeloid leukemia is yet another failed attempt by Astellas to add to Xospata’s label since US FDA approval in 2018.

Astellas Northbrook, IL
Astellas still has other avenues to label expansion for Xospata • Source: Shutterstock

Astellas Pharma, Inc.’s hopes for adding to the US label for Xospata in a mutated form of acute myeloid leukemia fell by the wayside on 9 March as the company revealed that the Phase III MORPHO study, which could have moved the drug into an earlier line of therapy, failed to meet its primary endpoint. The Tokyo-based firm will continue reviewing the study’s full dataset but said the trial will be stopped as it did not show a benefit for relapse-free survival (RFS) in the primary analysis.

Xospata (gilteritinib) is a second-generation inhibitor of FMS-like tyrosine kinase 3 (FLT3), mutations of which are associated with poorer therapeutic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By Joseph Haas

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

More from R&D